Real-World study tracks cholesterol drug inclisiran in heart patients
NCT ID NCT06958315
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This observational study follows about 198 patients in Spain who are already taking inclisiran (Leqvio) for high cholesterol linked to heart disease or a genetic condition. Researchers will check if patients reach their LDL cholesterol goals after 6 and 12 months. The goal is to see how the drug performs in everyday practice, outside of strict clinical trials.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Inclisiran (Leqvio)
What this could lead to
If successful, this study could show how well inclisiran works in everyday clinical practice, helping doctors better manage high cholesterol in patients with heart disease or genetic cholesterol disorders.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by other factors. It does not test new treatments or prove cause and effect.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATHEROSCLEROTIC CARDIOVASCULAR DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Cadiz, Andalusia, 11009, Spain
-
Novartis Investigative Site
Granada, Andalusia, 18014, Spain
-
Novartis Investigative Site
Huelva, Andalusia, 21005, Spain
-
Novartis Investigative Site
Jaén, Andalusia, 23007, Spain
-
Novartis Investigative Site
Marbella, Andalusia, 29600, Spain
-
Novartis Investigative Site
Mallorca, Balearic Islands, 07198, Spain
-
Novartis Investigative Site
Puerto Real, Cadiz, 11510, Spain
-
Novartis Investigative Site
Santander, Cantabria, 39008, Spain
-
Novartis Investigative Site
Andújar, Jaen, 23740, Spain
-
Novartis Investigative Site
Logroño, La Rioja, 26006, Spain
-
Novartis Investigative Site
San Cristóbal de La Laguna, Santa Cruz De Tenerife, 38320, Spain
-
Novartis Investigative Site
Burgos, 09006, Spain
-
Novartis Investigative Site
Córdoba, 14004, Spain
-
Novartis Investigative Site
Fuerteventura, 35600, Spain
-
Novartis Investigative Site
Las Palmas GC, 35010, Spain
-
Novartis Investigative Site
Málaga, 29010, Spain
-
Novartis Investigative Site
Salamanca, 37007, Spain
-
Novartis Investigative Site
Seville, 41009, Spain
-
Novartis Investigative Site
Seville, 41013, Spain